European Urology Oncology

Slides:



Advertisements
Similar presentations
Volume 69, Issue 5, Pages (May 2016)
Advertisements

Volume 68, Issue 6, Pages (December 2015)
European Urology Focus
Metastatic Castration-Resistant Prostate Cancer: Two Case Reports of Dramatic Response with Abiraterone Acetate in Patients Heavily Pretreated with Chemotherapy.
Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone.
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 58, Issue 4, Pages (October 2010)
Testosterone Therapy in Men With Prostate Cancer
Volume 69, Issue 5, Pages (May 2016)
Volume 68, Issue 6, Pages e129-e131 (December 2015)
Volume 60, Issue 2, Pages (August 2011)
Volume 67, Issue 4, Pages (April 2015)
Volume 68, Issue 4, Pages (October 2015)
Volume 66, Issue 5, Pages (November 2014)
European Urology Oncology
Volume 199, Issue 1, Pages (January 2018)
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.
European Urology Oncology
Volume 69, Issue 5, Pages (May 2016)
Volume 71, Issue 2, Pages (February 2017)
Volume 68, Issue 4, Pages (October 2015)
Volume 65, Issue 5, Pages (May 2014)
Volume 74, Issue 1, Pages (July 2018)
A Stepping Stone Toward Personalized Oncology: Genomic Analysis of Circulating Tumor Cells to Guide Management of Metastatic Castration-resistant Prostate.
Volume 65, Issue 3, Pages (March 2014)
Volume 65, Issue 1, Pages (January 2014)
Androgen Receptor Variants and Castration-resistant Prostate Cancer: Looking Back and Looking Forward  Takuma Uo, Cynthia Sprenger  European Urology 
Volume 71, Issue 1, Pages 1-3 (January 2017)
Volume 70, Issue 4, Pages (October 2016)
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Volume 70, Issue 5, Pages (November 2016)
Prostate Cancer Management: What Does the Future Hold?
Volume 66, Issue 3, Pages (September 2014)
Volume 66, Issue 5, Pages (November 2014)
Volume 70, Issue 5, Pages (November 2016)
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma  Viktor Grünwald, Xun Lin, Daniel Kalanovic,
Volume 70, Issue 4, Pages (October 2016)
Laurent Boccon-Gibod  European Urology Supplements 
Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients  Timo F.W. Soeterik,
Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers  Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 72, Issue 1, Pages (July 2017)
Volume 66, Issue 2, Pages (August 2014)
Volume 74, Issue 2, Pages (August 2018)
Volume 67, Issue 1, Pages (January 2015)
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.
Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G
Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography  Andrew.
Volume 71, Issue 6, Pages (June 2017)
European Urology Oncology
Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy  Matthew Mossanen, Kenneth.
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Volume 74, Issue 3, Pages (September 2018)
Volume 70, Issue 1, Pages (July 2016)
European Urology Oncology
Volume 71, Issue 4, Pages (April 2017)
Volume 75, Issue 3, Pages (March 2019)
European Urology Oncology
Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature  Liliana Vartolomei, Shahrokh F. Shariat, Mihai.
Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis  Joseph Sargon Joseph, Vincent.
Volume 69, Issue 5, Pages (May 2016)
European Urology Oncology
Axel Heidenreich  European Urology Supplements 
European Urology Oncology
European Urology Oncology
European Urology Oncology
Axel Heidenreich  European Urology Supplements 
European Urology Oncology
European Urology Oncology
Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.
Presentation transcript:

European Urology Oncology Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration- resistant Prostate Cancer Patients  Eleni Efstathiou, Mark Titus, Sijin Wen, Patricia Troncoso, Anh Hoang, Paul Corn, Ina Prokhorova, John Araujo, Carl Dmuchowski, Amal Melhem-Bertrandt, Shiva Patil, Christopher J. Logothetis  European Urology Oncology  DOI: 10.1016/j.euo.2019.01.008 Copyright © 2019 European Association of Urology Terms and Conditions

Fig. 1 (A) Kaplan-Meier plot of time to treatment discontinuation, (B) waterfall plot of prostate-specific antigen change from baseline at nadir, and (C) Kaplan-Meier plot of progression-free survival. CI=confidence interval; PFS=progression-free survival; PSA=prostate-specific antigen. European Urology Oncology DOI: (10.1016/j.euo.2019.01.008) Copyright © 2019 European Association of Urology Terms and Conditions

Fig. 2 Tumour AR-N terminal nuclear expression and downstream NKX3.1 expression using immunohistochemistry. AR=androgen receptor; H&E=haematoxylin and eosin stain. European Urology Oncology DOI: (10.1016/j.euo.2019.01.008) Copyright © 2019 European Association of Urology Terms and Conditions

Fig. 3 Ratio of AR-C/AR-N terminal expression and association with treatment benefit/primary resistance. AR=androgen receptor; H&E=haematoxylin and eosin stain. European Urology Oncology DOI: (10.1016/j.euo.2019.01.008) Copyright © 2019 European Association of Urology Terms and Conditions

Fig. 4 Waterfall plots of changes in (A and B) plasma and bone marrow testosterone and (C and D) plasma and bone marrow androstenedione at baseline and following 9wk of treatment. European Urology Oncology DOI: (10.1016/j.euo.2019.01.008) Copyright © 2019 European Association of Urology Terms and Conditions